Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ventricular Ejection Fraction Clear all
Completed Phase 4 Interventional

DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function

NCT00401687
View directory record Official record
Conditions
Ventricular Ejection Fraction
Interventions
Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Tucson, Arizona • Chicago, Illinois • Washington DC, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2011 · Synced Sep 24, 2026, 5:36 AM EDT
Recruiting Not applicable Interventional

Assessment of CCM in HF With Higher Ejection Fraction

NCT05064709
View directory record Official record
Conditions
Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure
Interventions
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
Device
Lead sponsor
Impulse Dynamics
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
105
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 24, 2026, 5:36 AM EDT
Terminated Phase 1 Interventional

Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.

NCT00622479
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Sorafenib (Nexavar, BAY43-9006)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Maywood, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)

NCT00684060
View directory record Official record
Conditions
Left Ventricular Dysfunction
Interventions
Adult stem cells, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Sep 24, 2026, 5:36 AM EDT
Completed No phase listed Observational

Left Ventricular Torsional Hysteresis: A Global Parameter for Diastolic Function

NCT01431027
View directory record Official record
Conditions
Heart Failure, Diastolic Heart Failure, Heart Failure With Normal Ejection Fraction
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function

NCT03357731
View directory record Official record
Conditions
Heart Failure, Cardiac Failure, Reduced Ventricular Ejection Fraction
Interventions
HNO Donor, Nitroglycerin (NTG), Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Tustin, California • Chicago, Illinois • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Sep 24, 2026, 5:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ventricular-Vascular Coupling in Heart Failure

NCT00207220
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
arterial tonometry, echocardiography
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 8, 2007 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)

NCT01300013
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Omecamtiv mecarbil
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
45
States / cities
Mobile, Alabama • Inglewood, California • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Not applicable Interventional

ECG AI-Guided Screening for Low Ejection Fraction

NCT04000087
View directory record Official record
Conditions
Asymptomatic Left Ventricular Systolic Dysfunction (Disorder), Heart Failure
Interventions
AI-enabled ECG-based Screening Tool
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 3 Interventional

Warfarin and Antiplatelet Therapy in Chronic Heart Failure

NCT00007683
View directory record Official record
Conditions
Heart Failure
Interventions
Warfarin titrated to an INR of 2.5-3.0, Aspirin, Clopidogrel 75
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
1,587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2011 · Synced Sep 24, 2026, 5:36 AM EDT
Recruiting Phase 3 Interventional

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

NCT06008197
View directory record Official record
Conditions
Heart Failure, Acute Heart Failure
Interventions
Finerenone, Placebo
Drug
Lead sponsor
Colorado Prevention Center
Other
Eligibility
18 Years and older
Enrollment
5,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
82
States / cities
Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 72 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

NCT03442764
View directory record Official record
Conditions
Non-obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamten, Placebo
Drug
Lead sponsor
MyoKardia, Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
32
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

NCT02678312
View directory record Official record
Conditions
Pediatric Heart Failure
Interventions
LCZ696, Enalapril, Placebo of LCZ696, Placebo of Enalapril
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
25
States / cities
Loma Linda, California • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 24, 2026, 5:36 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Imaging Histone Deacetylase in the Heart

NCT03549559
View directory record Official record
Conditions
Heart Failure With Normal Ejection Fraction, Left Ventricular Hypertrophy, Aortic Valve Stenosis, Diabetes
Interventions
11C-Martinostat, PET-MRI
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 24, 2026, 5:36 AM EDT
Active, not recruiting Not applicable Interventional

REsynchronization Comparison In LBBB and Normal or Mildly Reduced VENTricular Function With CRT (REINVENT-CRT)

NCT05652218
View directory record Official record
Conditions
Left Ventricular Ejection Fraction, Heart Failure (HF), Left Bundle-Branch Block
Interventions
LB-CRT, BIV-CRT
Device
Lead sponsor
Inova Health Care Services
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Durham, North Carolina • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Not applicable Interventional Results available

Understanding Outcomes With the EMBLEM™ S-ICD in Primary Prevention Patients With Low Ejection Fraction

NCT02433379
View directory record Official record
Conditions
Ventricular Fibrillation, Ventricular Tachycardia, Low Cardiac Output
Interventions
EMBLEM S-ICD System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
21 Years and older
Enrollment
1,173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
69
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Not applicable Interventional

Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)

NCT01354613
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Pulmonary Disease, Left Ventricular Hypertrophy/Hypertension
Interventions
Dobutamine, Amlodipine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Sep 24, 2026, 5:36 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

US Benchmarking Clinical Study

NCT07215715
View directory record Official record
Conditions
HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy), Left Ventricular Hypertrophy, Cardiac Amyloidosis
Interventions
Not listed
Lead sponsor
eMyosound SAS
Industry
Eligibility
60 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 24, 2026, 5:36 AM EDT
Terminated Phase 4 Interventional Results available

Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure

NCT00799435
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Heart Failure, Diastolic
Interventions
Exenatide
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 3 Interventional Results available

DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY

NCT03571672
View directory record Official record
Conditions
Cardiac Disease
Interventions
DEFINITY
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Tucson, Arizona • San Diego, California • Wilmington, Delaware + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 24, 2026, 5:36 AM EDT
Withdrawn No phase listed Observational

Left Ventricular Volume and Ejection Fraction: Validation of Real Time 3 Dimensional Transesophageal Echocardiography

NCT01734174
View directory record Official record
Conditions
3D Transesophageal and Transthoracic Echocardiogram
Interventions
transesophageal echocardiography (TEE), thermodilution, transthoracic echocardiography (TTE)
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Not applicable Interventional Results available

Optimize RV Follow-up Selective Site Pacing Clinical Trial

NCT00949715
View directory record Official record
Conditions
Cardiac Pacing, Right Ventricular Pacing, Left Ventricular Ejection Fraction
Interventions
Medtronic or Vitatron Dual-Chamber Pacemaker, Medtronic SelectSecure 3830 Lead
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Des Moines, Iowa • Silver Spring, Maryland • Southfield, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

NCT03624010
View directory record Official record
Conditions
Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction, Heart Failure With Normal Ejection Fraction
Interventions
Levosimendan
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
9
States / cities
Stanford, California • Chicago, Illinois • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 24, 2026, 5:36 AM EDT
Recruiting Phase 3 Interventional

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

NCT07288398
View directory record Official record
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
TNX-103, Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
46
States / cities
Alexander City, Alabama • Tucson, Arizona • Sacramento, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 24, 2026, 5:36 AM EDT